Journal
NATURE REVIEWS CANCER
Volume 9, Issue 10, Pages 749-758Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2723
Keywords
-
Categories
Funding
- National Cancer Institute, USA [R37 CA40099]
- Flight Attendant Medical Research Institute, USA
- European Commission [502983, 201102]
- Robert Bosch Foundation, Germany
- US National Institutes of Health [PO1 CA 87497]
- Department of Defense, USA [W81XWH-06-1-0514]
- Breast Cancer Research Foundation, USA
- Simons Foundation, USA
- NATIONAL CANCER INSTITUTE [P01CA087497, R37CA040099] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available